SciSparc (SPRC)

Executive Summary

SciSparc Ltd. (NASDAQ: SPRC) is a clinical-stage Israeli pharmaceutical company developing cannabinoid-based therapies for central nervous system disorders. Its lead programs target Tourette syndrome, Alzheimer's disease agitation and psychosis, and chronic pain, often combining cannabinoids with approved drugs for synergistic effects. The company holds intellectual property on its proprietary delivery systems and combinations. With a low market valuation of ~$3.6M and limited public information, SciSparc represents a high-risk, high-reward opportunity dependent on clinical trial progress and regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026Top-line data from Phase 2 trial for Tourette syndrome40% success
• Q3 2026Update on Alzheimer's agitation program30% success
• TBDPotential partnership or licensing deal20% success